The Cure Won't Pay the Bills

Moderna's melanoma trial results moved the stock this week — and a lot of the healthcare sector with it.

The excitement is real. Personalized, tumor-built cancer treatment is a genuine medical leap.

But here's the number that should temper the "this fixes healthcare spending" take: cancer treatment is only 6.7% of U.S. healthcare spend. Cure it completely, and the number that actually matters — the 20% of GDP we're on pace to hit by 2030 — barely moves.

This edition of The Weekly Insight covers:

→ What this "vaccine" actually is (hint: it's not what you think)
 → Why curing disease categories doesn't solve America's spending problem
 → Whether drug companies are even incentivized to find cures
 → What longer lifespans mean for an economy that needs workers, not just survivors

Read more here: https://insightwealthgroup.com/the-weekly-insight-the-cure-wont-pay-the-bills/